
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is set to see strong revenue growth in the coming years, driven by the ramp up of sales for its iDose TR implant and the strong performance of its other micro-scale surgical device products. The company's expansion into new areas of the eye with products such as Epioxa and its iLution platform, as well as its strong progress on market access and expanding its provider network, should lead to continued profitability and potential upside in the stock's valuation. Overall, with a robust product pipeline and strong sales execution, Glaukos looks poised for success in the future and remains a Buy at this time.
Bears say
Glaukos is well-positioned to continue its strong growth trajectory, particularly with the launch and ramp of its iDose and Epioxa products. The company's robust pipeline and potential market expansions provide further growth opportunities. However, there are risks to be considered, such as competition in the MIGS market and potential reimbursement issues. Despite these potential challenges, we see long-term potential for Glaukos with a Buy rating and a price target of $136.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares